A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in United Therapeutics Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 13,101 shares of UTHR stock, worth $4.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,101
Previous 14,201 7.75%
Holding current value
$4.73 Million
Previous $4.52 Million 3.78%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$311.04 - $363.55 $342,144 - $399,905
-1,100 Reduced 7.75%
13,101 $4.69 Million
Q2 2024

Aug 14, 2024

SELL
$228.26 - $319.04 $22.6 Million - $31.6 Million
-99,200 Reduced 87.48%
14,201 $4.52 Million
Q1 2024

May 15, 2024

BUY
$210.76 - $249.51 $20.4 Million - $24.2 Million
96,800 Added 583.1%
113,401 $26.1 Million
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $322,320 - $385,410
1,500 Added 9.93%
16,601 $3.65 Million
Q3 2023

Nov 14, 2023

SELL
$211.82 - $248.24 $1.42 Million - $1.66 Million
-6,700 Reduced 30.73%
15,101 $3.41 Million
Q2 2023

Aug 14, 2023

SELL
$205.19 - $232.99 $10.5 Million - $12 Million
-51,400 Reduced 70.22%
21,801 $4.81 Million
Q1 2023

May 15, 2023

SELL
$212.99 - $276.17 $3.98 Million - $5.16 Million
-18,700 Reduced 20.35%
73,201 $16.4 Million
Q4 2022

Feb 14, 2023

BUY
$205.95 - $280.43 $9.64 Million - $13.1 Million
46,800 Added 103.77%
91,901 $25.6 Million
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $182,970 - $219,753
900 Added 2.04%
45,101 $9.44 Million
Q2 2022

Aug 15, 2022

BUY
$174.81 - $241.14 $4.76 Million - $6.56 Million
27,201 Added 160.01%
44,201 $10.4 Million
Q1 2022

May 16, 2022

SELL
$166.16 - $213.96 $27 Million - $34.8 Million
-162,701 Reduced 90.54%
17,000 $3.05 Million
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $10.6 Million - $12.4 Million
-57,400 Reduced 24.21%
179,701 $38.8 Million
Q3 2021

Nov 15, 2021

BUY
$179.86 - $214.88 $38.6 Million - $46.1 Million
214,700 Added 958.44%
237,101 $43.8 Million
Q2 2021

Aug 16, 2021

SELL
$170.47 - $211.93 $1.84 Million - $2.29 Million
-10,801 Reduced 32.53%
22,401 $4.02 Million
Q1 2021

May 17, 2021

BUY
$153.94 - $174.85 $5.11 Million - $5.81 Million
33,202 New
33,202 $5.55 Million
Q4 2020

Feb 16, 2021

SELL
$101.87 - $151.79 $24.9 Million - $37.1 Million
-244,602 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$99.9 - $121.13 $13.5 Million - $16.4 Million
-135,001 Reduced 35.56%
244,602 $24.7 Million
Q2 2020

Aug 14, 2020

BUY
$92.74 - $125.82 $139,110 - $188,730
1,500 Added 0.4%
379,603 $45.9 Million
Q1 2020

May 15, 2020

SELL
$79.39 - $115.35 $1.9 Million - $2.76 Million
-23,900 Reduced 5.95%
378,103 $35.9 Million
Q4 2019

Feb 14, 2020

SELL
$78.31 - $95.34 $7.35 Million - $8.95 Million
-93,900 Reduced 18.94%
402,003 $35.4 Million
Q3 2019

Nov 14, 2019

SELL
$74.85 - $85.99 $366,765 - $421,351
-4,900 Reduced 0.98%
495,903 $39.5 Million
Q2 2019

Aug 14, 2019

BUY
$76.06 - $120.81 $33.1 Million - $52.5 Million
434,730 Added 657.95%
500,803 $39.1 Million
Q1 2019

May 15, 2019

SELL
$107.15 - $126.84 $2.15 Million - $2.55 Million
-20,100 Reduced 23.33%
66,073 $7.76 Million
Q4 2018

Feb 14, 2019

SELL
$101.4 - $128.73 $253,500 - $321,825
-2,500 Reduced 2.82%
86,173 $9.38 Million
Q3 2018

Nov 14, 2018

BUY
$113.81 - $129.46 $3.41 Million - $3.88 Million
30,000 Added 51.13%
88,673 $11.3 Million
Q2 2018

Aug 14, 2018

BUY
$101.14 - $118.31 $4.98 Million - $5.82 Million
49,200 Added 519.37%
58,673 $6.64 Million
Q1 2018

May 15, 2018

SELL
$107.21 - $151.94 $943,448 - $1.34 Million
-8,800 Reduced 48.16%
9,473 $1.06 Million
Q4 2017

Feb 14, 2018

BUY
$118.58 - $151.28 $1.83 Million - $2.33 Million
15,402 Added 536.47%
18,273 $2.7 Million
Q3 2017

Nov 14, 2017

BUY
$114.6 - $136.81 $329,016 - $392,781
2,871
2,871 $336,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.